title: Cyclooxygenase-2 single-nucleotide polymorphisms and hepatocellular carcinoma in Egypt.
abstract: Hepatocellular carcinoma (HCC) is a worldwide neoplasm for which early diagnosis is difficult and the prognosis is usually poor. Overexpression of cyclooxygenase 2 (COX-2) has been suggested to be associated with hepatocarcinogenesis. Although several COX-2 inhibitors have been used in hepatoma therapy, the genetic background between COX-2 and HCC remains largely unknown. In this study, the association of genotypic polymorphisms in COX-2 with HCC was investigated. 25 healthy individuals served as control (group I), group II: 50 HCV infection patients without any complications, group III: 50 HCV infected patients complicated with cirrhosis and group IV: 75 HCV infected patients complicated with (45 localized and 30 metastatic) HCC from Zagazig University Hospital in Egypt were genotyped by a PCR-RFLP method. The results showed that, no differences in distribution between the HCC and other groups were found. We found -1195A allele carriers had a higher risk of HCC with HCV infection. As regard the obtained results of serum AFU, a significant increase was detected in HCC as compared with cirrhosis, hepatitis and healthy control groups (p < 0.001). Concerning the obtained results of serum AFP, when HCC group was compared with cirrhosis, hepatitis and healthy controls, a significant increase was observed (p < 0.001).
  
  
  CONCLUSIONS
  identification of SNP in COX-2 gene promoter and evaluation of serum AFU and AFP give a red light in early detection of HCC which may be reduce its fatal incidence.
authors.affiliation: Biochemistry Division, Chemistry Department, Faculty of Sciences, Zagazig University, Zagazig, Egypt, memozad7@yahoo.com.
authors.forename: Faten Zahran
authors.initials: FZ
authors.lastname: Mohamed
authors.forename: Yousry Mostafa
authors.initials: YM
authors.lastname: Hussein
authors.forename: Ibrahim Mohey
authors.initials: IM
authors.lastname: El-Deen
authors.forename: Marwa Sayed
authors.initials: MS
authors.lastname: Sabea
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000235:genetics* / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000235:genetics*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D004534:Egypt; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000235:genetics; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000235:genetics; D008113:Liver Neoplasms / Q000150:complications / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: C097353:AFP protein, human; D052246:Cyclooxygenase 2 Inhibitors; D000509:alpha-Fetoproteins; D051546:Cyclooxygenase 2